39061-97-7Relevant articles and documents
Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia
Yang, Jincheng,Chen, Kun,Wang, Bin,Wang, Liudi,Qi, Shuya,Wang, Weihua
, p. 79 - 91 (2020)
Hair loss is a common dermatosis symptom and side-effect in cancer chemotherapeutics. Imiquimod application at mid and late telogen activated the hair follicle stem cells leading to premature hair cycle entry. Based on quinoline structure, a newly synthesized compound 6b displayed proliferation activity in vitro and in vivo through branch chain replacement and triazole ring cyclization. Toll-like receptors (TLRs) are also critical mediators of the immune system, and their activation is linked to various diseases. The present study aimed to expand new agonists within co-crystallization of TLR7 (PDB code: 5GMH); however, biological assays of NF-κB activity and NO-inhibition indicated that five selected compounds were TLR7 antagonists. Molecular docking indicated the binding mode differences: antagonists binding TLR7 in a different direction and interacting with adjacent TLR7 with difficulty in forming dimers.
Synthesis of quinoline based molecular probes for detection of nitric oxide
Kansal, Sushil K.,Kaur, Manpreet,Kaushik, Deepender,Mehta, Surinder K.,Mutreja, Vishal,Pathania, Khushboo,Pawar, Sandip V.,Sahoo, Subash Chandra,Saini, Vaneet,Salunke, Deepak B.
, (2022/03/31)
Nitric oxide (NO), an important signaling molecule of the immune, vascular and nervous system was found to be present in different concentrations in biological fluids such as blood and plasma as well as in neural tissue and endothelium. A variety of competent probes may be required to detect NO and understand its complicated biochemistry, and establish the correlation of its concentrations among different biological media to its biological effect. In order to find new probes as NO sensors, four quinoline-derived ortho-diamines were synthesized and their structures and purities were confirmed by various spectroscopic methods including single-crystal X-ray diffraction. The molecules were investigated for the bimodal sensing (UV–visible and fluorescence) potential for NO. All the probes have showcased both UV–visible and fluorescent signals towards the presence of NO due to the formation of corresponding triazoles. Interestingly, the limit of detection was observed in the nanomolar range (56.1–95 nM) for the four ligands using colorimetric signals. Among the prepared molecules, the N4-(4-chlorobenzyl)quinoline-3,4-diamine exhibited superior sensing parameters viz the limit of detection (LOD), formation constant (Kf), and quenching constant (Ksv). An isolated triazole further confirmed the proposed mechanism of NO detection.
IMIDAZOQUINOLINE-TYPE COMPOUNDS AND USES THEREOF
-
, (2021/10/11)
Provided in the present disclosure are imidazoquinoline-type compounds, methods for their preparation, pharmaceutical compositions thereof and their use, wherein the imidazoquinoline-type compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.
LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES
-
, (2020/10/19)
Provided in the present disclosure are immunotherapy compounds, pharmaceutical compositions thereof and their use, wherein the immunotherapy compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.
TOLL-LIKE RECEPTOR 8 (TLR8)-SPECIFIC ANTAGONISTS AND METHODS OF MAKING AND USES THEREOF
-
Page/Page column 83, (2019/05/22)
Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.
SUBSTITUTED IMIDAZOQUINOLINES
-
Page/Page column 41, (2019/04/10)
The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.
SUBSTITUTED IMIDAZOQUINOLINES AS AGONISTS OF TLR7
-
Page/Page column 41-42, (2019/04/10)
The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.
Nitrogenous five-membered heterocycle quinoline compound and salt, preparation method, pharmaceutical composition and application thereof
-
Paragraph 0064; 0070, (2018/05/30)
The invention relates to a nitrogenous five-membered heterocycle quinoline compound and a salt, a preparation method, a pharmaceutical composition and application thereof. The structural formula of the nitrogenous five-membered heterocycle quinoline compound is shown by I in the description; the preparation method of the nitrogenous five-membered heterocycle quinoline compound comprises the following steps: with a 4-hydroxyquinoline compound as a starting raw material, sequentially performing nitrification, halogenation, amination, reduction and cyclization reaction to obtain a final product.The nitrogenous five-membered heterocycle quinoline compound and the pharmaceutically acceptable salt thereof have the advantages that a hair follicle proliferation function can be realized and can beused for preparing medicines for treating common alopecia, alopecia caused by chemoradiotherapy and hair follicle damage.
NLRP3 MODULATORS
-
Page/Page column 63; 64, (2017/11/15)
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonize or partially agonize) NLRP3 and TLR7 and/or TLR8 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 and TLR7 and/or TLR8 activities (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 and TLR7 and/or TLR8 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
Dual inhibitors of epidermal growth factor receptor and topoisomerase IIα derived from a quinoline scaffold
Chauhan, Monika,Joshi, Gaurav,Kler, Harveen,Kashyap, Archana,Amrutkar, Suyog M.,Sharma, Praveen,Bhilare, Kiran D.,Chand Banerjee, Uttam,Singh, Sandeep,Kumar, Raj
, p. 77717 - 77734 (2018/06/22)
Based on the quinazoline bearing EGFR inhibitors, a series of thirty four compounds having a quinoline scaffold were synthesised and evaluated in vitro for EGFR kinase inhibitory activity. A structure-activity relationship study revealed that 2,4-bis(arylamino) substituted quinolines possessed better anti-EGFR kinase activity. Compounds 3f and 3m emerged as potent EGFR kinase inhibitors (200 and 210 nM, respectively) and showed excellent anticancer activity at the micromolar level against a panel of cancer cell lines comparable to erlotinib. Furthermore, representative compounds inhibited the human topoisomerase IIα selectively and catalytically, did not intercalate with DNA, increased intracellular ROS concentration (except 3m) and altered the mitochondrial membrane potential of the cancer cells. Cell cycle analysis and annexin-V staining in a lung cancer cell line showed that the compounds delayed cell cycle progression by inducing cell cycle arrest and subsequent apoptosis at the G1 phase. The facts were further corroborated through molecular modeling studies.
